(VIANEWS) – BOIRON (BOI.PA) is among this list of stock assets with the highest dividend rate and return on equity on the Healthcare sector.
| Financial Asset | Price | Forward Dividend Yield | Return on Equity |
|---|---|---|---|
| BOIRON (BOI.PA) | €39.25 | 2.82% | 8.13% |
| CEGEDIM (CGM.PA) | €18.92 | 2.6% | 5.08% |
| ESSILORLUXOTTICA (EL.PA) | €174.40 | 1.75% | 6.16% |
| TUBIZE-FIN (TUB.BR) | €73.60 | 1.11% | 4.93% |
Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. BOIRON (BOI.PA)
2.82% Forward Dividend Yield and 8.13% Return On Equity
Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers non-proprietary, proprietary, branded homeopathic medicines. Its branded homeopathic medicines include Oscillococcinum to treat influenza symptoms, such as fever, chills, headaches, and aches; Stodal and Stodaline for treating coughs; Arnigel for adjunctive local treatment of benign trauma in the absence of open wounds; Camilia for the treatment of teething problems for babies; and Sédatif PC to treat anxiety and emotional, and minor sleep disorders. The company's homeopathic medicines also comprise Coryzalia for the treatment of cold symptoms and rhinitis; Homéoptic to treat eye discomfort and irritation due to various causes for adults and children; and Homéovox for vocal disorders. In addition, it provides dietary supplement; Dermoplasmine stick, baume, and mousse to treat dry lips and skin; Mag' Nuit, a formula to fall asleep; Arnitrosium for joint pain; Castor Equi Boiron ointment for treatment of cracked skin; and Storinyl, a syrup to treat colds. Further, it offers herbal medicines, such as Canephron to increase the amount of urine and to improve urinary elimination; moisturizing baby milk; and medical devices, including a range of COVID self-tests and rapid antigenic tests. The company offers its products through distribution centers, pharmacies, pharmacy chains, wholesalers, grocery and drugstores, health food stores, and online retail. Boiron SA was founded in 1932 and is headquartered in Messimy, France.
Earnings Per Share
As for profitability, BOIRON has a trailing twelve months EPS of €2.89.
PE Ratio
BOIRON has a trailing twelve months price to earnings ratio of 13.58. Meaning, the purchaser of the share is investing €13.58 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.13%.
Yearly Top and Bottom Value
BOIRON’s stock is valued at €39.25 at 12:30 EST, way below its 52-week high of €53.20 and higher than its 52-week low of €37.70.
Moving Average
BOIRON’s worth is under its 50-day moving average of €39.83 and way below its 200-day moving average of €44.07.
Volatility
BOIRON’s last week, last month’s, and last quarter’s current intraday variation average was 0.23%, 0.22%, and 1.09%.
BOIRON’s highest amplitude of average volatility was 0.55% (last week), 0.80% (last month), and 1.09% (last quarter).
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Jun 1, 2023, the estimated forward annual dividend rate is 1.1 and the estimated forward annual dividend yield is 2.82%.
More news about BOIRON.
2. CEGEDIM (CGM.PA)
2.6% Forward Dividend Yield and 5.08% Return On Equity
Cegedim SA operates as a technology and services company in the digital data flow management for healthcare ecosystem and B2B, and business software publisher for healthcare and insurance professionals worldwide. It operates in two divisions, Health Insurance, HR and e-Services; and Healthcare Professionals. The Health Insurance, HR and e-Services division markets various products and services to insurance companies, mutual insurers, personal protection insurers, and insurance brokers, as well as engages in the interactions between these entities and healthcare professionals. This division also provides solutions for hosting, HR and payroll management outsourcing, and electronic data exchange services. The Healthcare Professionals division offers management software, databases, and solutions to doctors, allied health professionals, pharmacists, and healthcare facilities. The company was incorporated in 1969 and is headquartered in Boulogne-Billancourt, France. Cegedim SA is a subsidiary of FCB SA.
Earnings Per Share
As for profitability, CEGEDIM has a trailing twelve months EPS of €1.
PE Ratio
CEGEDIM has a trailing twelve months price to earnings ratio of 18.92. Meaning, the purchaser of the share is investing €18.92 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.08%.
More news about CEGEDIM.
3. ESSILORLUXOTTICA (EL.PA)
1.75% Forward Dividend Yield and 6.16% Return On Equity
EssilorLuxottica Société anonyme engages in design, manufacture, and distribution of ophthalmic lenses, frames, and sunglasses in Europe, Middle East, Africa, Latin America, Asia-Pacific, and North America. It operates through Professional Solutions and Direct to Consumer segments. The company offers lens under the Crizal, Essilor, Eyezen, Stellest, Xperio, Optifog, Satisloh, Barberini, Shamir, Nikon, KODAK Lens, Oakley, OPTIFOG, Ray-Ban, Transitions, Vailux, and Xperio brands. It also provides eyewear products under the Ray-Ban, Oakley, Persol, Oliver Peoples, Alain Mikli, Costa del Mar, Native Eyewear, Luxottica, Sferoflex, Heritage, Sensaya, Miki Ninn, DbyD, Unofficial and Seen, Arnette, Vogue Eyewear, Bolon, Molsion, and Ossé, as well as other Licensed brands. In addition, the company designs, develops, markets, and maintains lens edging and mounting instruments for opticians and prescription laboratories; and optometry instruments for eyecare professionals, schools, occupational medicine centers, military, and other institutions. It wholesales its products to independent opticians, distributors, third-party e-commerce platforms, and large retail chains in the eyecare and eyewear industry; and sells directly to consumers through the network of physical stores or its online channels. The company was formerly known as Essilor International Société Anonyme and changed its name to EssilorLuxottica Société anonyme in October 2018. EssilorLuxottica Société anonyme was founded in 1849 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, ESSILORLUXOTTICA has a trailing twelve months EPS of €4.83.
PE Ratio
ESSILORLUXOTTICA has a trailing twelve months price to earnings ratio of 36.11. Meaning, the purchaser of the share is investing €36.11 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.16%.
Volume
Today’s last reported volume for ESSILORLUXOTTICA is 105778 which is 78.1% below its average volume of 483203.
Volatility
ESSILORLUXOTTICA’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.27%, a negative 0.23%, and a positive 1.04%.
ESSILORLUXOTTICA’s highest amplitude of average volatility was 1.27% (last week), 0.79% (last month), and 1.04% (last quarter).
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, ESSILORLUXOTTICA’s stock is considered to be overbought (>=80).
Moving Average
ESSILORLUXOTTICA’s worth is above its 50-day moving average of €168.07 and higher than its 200-day moving average of €164.43.
More news about ESSILORLUXOTTICA.
4. TUBIZE-FIN (TUB.BR)
1.11% Forward Dividend Yield and 4.93% Return On Equity
Financière de Tubize SA, through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases. The company's products include Cimzia for treating ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Briviact, Vimpat, and Keppra for the treatment of epilepsy partial-onset seizures; Nayzilam, a nasal spray; and Neupro for treating Parkinson's disease and restless legs syndrome. It also offers Evenity, an injection for osteoporosis; and Bimzelx to treat moderate to severe plaque psoriasis. The company's products in pipeline include Staccato to treat stereotypical prolonged seizures; Bepranemab for the treatment of Alzheimer's disease; UCB0599 for Parkinson's disease; bimekizumab to treat psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, myelin oligodendrocyte glycoprotein antibody disease, and autoimmune encephalitis; and dapirolizumab pegol for systemic lupus erythematosus. Financière de Tubize SA is based in Brussels, Belgium.
Earnings Per Share
As for profitability, TUBIZE-FIN has a trailing twelve months EPS of €1.91.
PE Ratio
TUBIZE-FIN has a trailing twelve months price to earnings ratio of 38.53. Meaning, the purchaser of the share is investing €38.53 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.93%.
Yearly Top and Bottom Value
TUBIZE-FIN’s stock is valued at €73.60 at 12:30 EST, way below its 52-week high of €83.70 and way above its 52-week low of €65.40.
Volume
Today’s last reported volume for TUBIZE-FIN is 2026 which is 70.5% below its average volume of 6869.
More news about TUBIZE-FIN.
